Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

33
Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

2018-07-13 seekingalpha
Discussion: ResTORbio (TORC) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infection-lowering ability. The datasets were published in Science Translational Medicine. The study showed that RTB101 both as monotherapy as well as in combination with Novartis’s Afinitor (everolimus), showed statistically significant reduced rate of respiratory tract infections.
SNWW AST ACHV URGN CDXC OVID AUPH SNWV DRNA AKCA TORC AUP AST.WS OSIR AGN MRK IONS NVS ABBV RMD BMY ABBV

26
Where Did Major Pharma Short Sellers Go?

2018-07-12 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
PFZ TEVJF MRK TEVA TEVVF ABBV LLY 500680 PFE PFIZER ABBV BMY

4
Company Spotlight: Forty Seven

2018-07-11 seekingalpha
Forty Seven is well-positioned to continue advancing their anti-CD47 antibody, Hu5F9, towards a potential first-in-class checkpoint inhibitor targeting the innate immune system.
MRK SURF FTSV TRIL BMY

25
7 Small-Cap Stocks to Consider for the Second Half of 2018

2018-07-09 investorplace
Small-cap stocks continue to put some distance between themselves and their large-cap brethren. Though the Dow Jones Industrial Average and the S&P 500 ended Monday’s trading in the red on lingering fears of a trade war, once again the Russell 2000 Small Cap Index mustered a gain most other market indices couldn’t. Indeed, it’s likely that small-cap stocks are outpacing large-cap alternatives specifically because they’re better shielded from an international trade war.
TTMI RUN PBH USNA AOBC NVDA GSK OSUR JNJ MRK CDXS INTC

14
Johnson & Johnson Stock Only Benefits from Big Moves That May Not Come

2018-07-09 investorplace
One of the most often used arguments in favor of owning Johnson & Johnson (NYSE:JNJ) is its diversity. JNJ stock isn’t just an investment in some of the pharmaceutical industry’s most critical drugs. It’s also an investment in some of the market’s most basic off-the-shelf personal care goods as well as a stake in a medical equipment business most investors simply forget about.
JNJ MRK PFE

26
Merck Has The Best Anti-Cancer Portfolio - Cramer's Lightning Round (7/6/18)

2018-07-09 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, July 6.
IBM FDS CARA NLY NLY.PRA NLY.PRECL NLY.PRD NLY.PRE NLY.PRC BABA NLY.PRF NLY.PRG PPG MRK YRD BIDU

53
Sector ETF Week In Review For The Week Of July 2-6

2018-07-08 seekingalpha
There's good and bad news here. The good news is that most sectors rose. In fact, only one sector (Energy) was down and its loss was marginal. But the bad news is that the strongest sectors were defensive. Healthcare rose the most, followed by utilities. The XLP (consumer staples) was the fourth strongest sector.
PM FB PG GILD GOOG CVS V T CL MRK GOOGL JNJ AAPL KO VZ CSCO MSFT INTC PFE BMY MO

22
Forty Seven IPO: Google Has A Stake, But Other Competitors Trade At Lower Valuations

2018-07-06 seekingalpha
Entities affiliated with Google own 5.2% stake in the company. Clients of Wellington Management Company have 6.8% stake as well.
ORPHF ABT MKGAF AMGN CELGZ GILD SURF GOOG TRIL ABT RHHBF ARTH RHHVF MKGAY MRK CELG RHHBY FTSV PDLI

15
Don’t Buy Biogen Stock on the Promise of an Alzheimer’s Breakthrough

2018-07-06 investorplace
Biogen (NASDAQ:BIIB) is the hot stock of the moment thanks to success in a trial of an Alzheimer’s drug. BAN2401, an antibody, seemed to slow the progress of the disease after those in early stages took it for 18 months. It operates by reducing the amount of a protein called beta amyloid. Progress on Alzheimers makes Biogen stock worth at least a look, right?
BIIB MRK JNJ IBB

15
Trade of the Day: Novocure Ltd (NVCR) | InvestorPlace

2018-07-06 investorplace
To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
PFZ NVCR JNJ MRK XHUA 500680 PFE PFIZER

18
Intel, Walgreens Pace the Dow Thursday

2018-07-05 247wallst
July 5, 2018: Markets opened higher again Thursday following an offer from the United States to withhold imposing a duty on car imports from the European Union if the EU eliminates its duties. The devil will be in the details. The Fed released the minutes from the last FOMC meeting signaling an end to monetary stimulation but worrying at the same time about the impact of tariffs on business investment and economic growth, both of which the Fed had been sanguine about.
JNJ MRK WBA INTC

28
Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

2018-07-03 seekingalpha
RedHill Biopharma (RDHL) announced that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The patents will be in effect until 2029. The company has an important upcoming catalyst related to its RHB-104 candidate. Topline Phase 3 data of RHB-104 trial MAP-US on Crohn's disease expected in early August 2018.
NLNK REDIF ALKS RDHL INCY TLGT OBMP CTIC CTI JAGX SHPG NVTR MRK CELG

3
FDA Accepts Merck’s Keytruda for Review, Sets PDUFA Date

2018-07-02 247wallst
Merck & Co. Inc. (NYSE: MRK) shares retreated to start off the week after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted Keytruda for review for a supplemental Biologics License Application (sBLA). This is Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel as a first-line treatment for metastatic squamous non-small cell lung cancer.
MRK

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to MRK / Merck & Co., Inc. on message board site Silicon Investor.

MRK: Merck u0026 Co., Inc. Merck
Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) MERCK
The Quack Is In MRKL - Markland Technologies, Inc.
MMRK - Mile Marker International, Inc. QMRK-QUALMARK
DMRK- Damark International- The Next One? Marker International MRKR Ski Bindings,clothing,snowboards
CUSIP: 58933Y105